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Abstract
We hypothesize that the phenomenon of allele-specific methylation (ASM) may underlie the phenotypic effects of multiple
variants identified by Genome-Wide Association studies (GWAS). We evaluate ASM in a human population and document its
genome-wide patterns in an initial screen at up to 380,678 sites within the genome, or up to 5% of the total genomic CpGs.
We show that while substantial inter-individual variation exists, 5% of assessed sites show evidence of ASM in at least six
samples; the majority of these events (81%) are under genetic influence. Many of these cis-regulated ASM variants are also
eQTLs in peripheral blood mononuclear cells and monocytes and/or in high linkage-disequilibrium with variants linked to
complex disease. Finally, focusing on autoimmune phenotypes, we extend this initial screen to confirm the association of
cis-regulated ASM with multiple complex disease-associated variants in an independent population using next-generation
bisulfite sequencing. These four variants are implicated in complex phenotypes such as ulcerative colitis and AIDS
progression disease (rs10491434), Celiac disease (rs2762051), Crohn’s disease, IgA nephropathy and early-onset
inflammatory bowel disease (rs713875) and height (rs6569648). Our results suggest cis-regulated ASM may provide a
mechanistic link between the non-coding genetic changes and phenotypic variation observed in these diseases and further
suggests a route to integrating DNA methylation status with GWAS results.
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Introduction
In recent years, Genome Wide Association Studies (GWASs)
have unearthed thousands of disease associated DNA sequence
variants. As the majority of these variants are non-coding, their
functional roles have been difficult to identify. Recent evidence
showing enrichment of expression Quantitative Trait Loci
(eQTLs) within these uncategorized groups of variants [1] suggests
they can affect phenotype by regulating gene expression levels,
likely through their effects on regulatory mediators. Indeed,
GWAS-derived variants are enriched for regulatory marks such as
DNAse hypersensitivity [2] and various chromatin states [3,4].
Evidence also suggests that DNA methylation [5], an epigenetic
process that can regulate gene expression [6], may also mediate
genetic variants’ phenotypic effects [7]. While studies of DNA
methylation have typically focused on either CpG islands or
differentially methylated regions associated with genomic imprint-
ing, studies [8–11] have demonstrated a novel type of differential
methylation where the methylation mark is consistently associated
with one allele. Often termed allele-specific methylation (or ASM),
the phenomenon can be influenced to varying degrees by DNA
sequence within a population, ranging from complete association
of methylation and genotype (i.e. cis-regulated ASM) [9–11], to
more stochastic associations, where either allele may be associated
with the methylation mark. As ASM is associated with expression
changes in nearby genes, this genetic control of cis-regulated
differential methylation has the potential to affect phenotypic
variation [10–13].
Here we investigate 1) genome-wide/population patterns of
ASM, including genomic features of ASM regions; and 2) the
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types and genetic variants that control ASM to identify individual
ASM loci associated with complex traits. To do so, we employ a
recently developed method that utilizes single nucleotide poly-
morphism (SNP) genotyping arrays [8,9] in an initial screen to
systematically identify cis-regulated ASM in a population. We then
verify a subset of these cis-regulated ASM regions in an
independent population by targeted next-generation bisulfite
sequencing. Our findings show that cis-regulated ASM can be
associated with intergenic variants linked to both expression and
phenotypic variation, suggesting it could provide a mechanistic
link between the non-coding genetic changes and phenotypic
variation observed in many GWA studies.
Results
We performed an initial screen for ASM in whole blood using a
microarray method based method and confirmed a small subset of
these loci using next-generation bisulfite sequencing.
Microarray Based Detection of Allele-Specific Methylation
The initial microarray screen was based on detecting ‘‘loss of
heterozygosity’’ signals after amplicon ablation by methylation
sensitive restriction enzyme (MSRE) based digestion at sites
nearby one of the two alleles. Using Affymetrix SNP 6.0 arrays we
looked for allelic ratio changes of these MSRE positive regions
(MPRs) after MSRE digestion of genomic DNA derived from
whole blood. We adjusted for both probe-specific and sample
specific biases by adjusting for the variation observed for
individual SNP probes within HapMap samples and the variation
observed for MSRE negative regions (or MNRs) within an
individual sample, respectively (Figure 1).
To lower the chance of erroneously calling ASM we filtered out
MPRs with 1) poor genotype discrimination by allelic ratio and
genotype calling rate in the HapMap samples, 2) non-ideal
predicted amplicon size, and 3) predicted presence of MSRE
modifying SNPs (Figure S1). After quality control filtering, our
assay can theoretically examine a maximum of 380,678 MPRs in
an individual, were all SNPs to be heterozygous in that individual.
More plausibly, because any given individual is heterozygous for
,25% of SNPs, our assay interrogates approximately 100,000
different MPRs per individual. These MPRs contain 1,278,397
MSRE sites in total; with each MSRE site assaying one CpG, a
maximum of ,5% of the total genomic CpGs are assayed. A final
filter acted to remove MPRs with low overall intensities in
individual samples as the allelic ratios of these MPRs are overly
affected by background noise, leaving a median number of 58,173
MPRs available for assay in each individual.
Using this methodology, we examined ASM patterns in whole
blood samples derived from 42 individuals from the National
Academy of Sciences-National Research Council World War II
Veteran Twin Registry. We were able to see ASM at multiple sites
known to exhibit ASM (Figure S2). Of the 5 cis-regulated ASM
sites and the 8 imprinted DMRs from Schalkwyk et al. [11] that
we could assay, we found that 5/5 show ASM and 7/8 show some
level of monoallelic methylation, respectively. The allele preferred
for ASM in our study was consistent with that observed by
Schalkwyk et al. Of the 297,333 SNPs with at least one
heterozygote sample, 127,292 show at least one ASM event
within the sample population. Our allele-specific methylation
assay is based on empirical cutoffs that exclude 95% of MNRs (for
more details, see Information S1), and as such would be expected
to exhibit a 5% false positive rate when assessing MPRs. We
observed candidate ASM levels that were significantly higher than
this expected false positive rate of 5%, with a mean rate of 7.8%
ASM (or 1.6 fold higher than the expected false positive rate)
(Table S1).
Population Characteristics of Allele-Specific Methylation
Candidates
We proceeded to attempt to identify candidates for cis-regulated
ASM in this population. The extent to which a given MPR can be
assessed for ASM is dependent upon the number of individuals
heterozygous for each SNP, the strength of the ASM event, and
the background noise of ASM (which may be due to technical
artifact or stochastic variation in methylation itself). For the
purposes of our study, we limited our analysis to MPRs with at
least 6 heterozygous individuals in order to obtain robust statistics
for ASM. Of the 242,533 MPRs eligible for analysis, 126,488
(52%) showed zero ASM events and 116,045 (48%) had at least
one ASM event.
To minimize the number of false positive ASM events, we
focused on 12,032 MPRs with at least 6 ASM events. We picked
this threshold, as it is the minimum number of samples necessary
to yield a p-value of less than 0.05 in an exact binomial test. Of
these candidate ASM events, 9,750 (,81%) showed non-random
allelic choice (i.e. for a given amplicon ASM events were on the A
allele or all were on the B allele) and 2282 (,19%) failed to reject
the null hypothesis of random allelic choice (i.e.. we observed a
mix between A allele and B allele ASM). That is, of the 242,533
MPRs eligible for analysis, 9,750 MPRs (or 4% of the total)
showed evidence for cis-regulated ASM in our study population of
42 individuals (Figure 2A). Note that while MPRs with apparently
random allelic choice may be imprinted, it is not possible to infer
their prevalence from this statistic, as failure to reject the null
hypothesis does not entail it’s acceptance. Representative exam-
ples are shown in Figure 2B (Figure 2).
Properties of Cis-Regulated ASM Candidates
To identify interesting subsets of these candidate cis-regulated
ASM variants to study further, we examined 1) their genomic
positions relative to genes 2) their status in two sets of Expression
Quantitative Trait Loci (eQTLs) from appropriate cell types
(monocytes and peripheral blood monocytes (PBMCs)) [14–16]
and 3) their status in the set of GWAS variants curated by the
National Human Genome Research Institute [17]. For the latter
two steps, the candidate ASM SNP sets were pruned to remove
SNPs in linkage disequilibrium (LD), yielding a mean of 8,147 cis-
regulated ASM SNPs.
A majority of the candidate cis-regulated ASM associated SNPs
were upstream or downstream of a gene (6113/9687 SNPs, or
63.1%) as opposed to within the gene body (defined as within the
59UTR, 39UTR, exon, or intron of an annotated gene) (Figure
S3A). These non-genic candidate cis-regulated ASM SNPs were a
median distance of ,129 kb from the closest gene (Figure S3B).
Multiple LD-pruned SNPs associated with candidate cis-regulated
ASM were eQTLs in either monocytes (1752/8147) or PBMCs
(906/8147). Finally, multiple candidate variants associated with
cis-regulated ASM were in high LD (r
2.0.80) with a variant
drawn from the NHGRI GWAS catalog (average 90/8147 in 10
LD-pruned NHGRI GWAS SNP sets respectively) (Table 1).
These GWAS variants were associated with a number of
phenotypes, including such medically relevant phenotypes as
autoimmunity, coronary heart disease, obesity, and type 2
diabetes. These findings provided us with a subset of candidate
cis-regulated ASM loci that are biologically relevant for both
disease and gene expression phenotypes (Table S2).
Allele Specific Methylation at Disease Variants
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To independently confirm some of these candidate cis-regulated
ASM loci, we performed a complementary assay (bisulfite
sequencing) in an independent collection of healthy control
subjects (n=82). We prioritized regions for further investigation
based on the following criteria: (1) the cis-regulated MPR must
contain both a genetic variant and an MSRE site within a
minimally sized target amplicon (n=500 bp); (2) strength of ASM
signal, defined as the percentage of heterozygous individuals with
ASM; (3) association of the target SNP (or a SNP in high LD) with
risk of an autoimmune disease, as determined from the NHGRI;
and when possible (4) association of the target SNP (or a SNP in
high LD) with an eQTL. We chose autoimmunity as a relevant
phenotype because our ASM assays were done using whole blood
samples, and many autoimmune risk alleles disrupt the function of
genes expressed in whole blood. As controls, variants were also
targeted based on their known ASM status (2) or lack of
association with ASM (1) in our microarray data. After quality
control filtering (see Methods), we examined 10 sites in 70
individuals; amplicons comprised two known ASM regions, one
non-ASM region from our microarray studies and seven ASM
regions found to be in high LD with GWAS variants.
As an initial step, to increase our ability to identify ASM
associated variants in our set of targets, we combined the reads
from all samples, and examined the association of methylation
status with allele identity by chi-square analyses. Of the ten
amplicons examined, two were positive controls (rs943049 and
rs9366927) and seven (rs10491434, rs2021716, rs2564921,
rs2762051, rs6569648, rs713875, rs884488) were variants in high
LD with (or identical to) phenotypic variants that show evidence of
Figure 1. Microarray based detection of allele-specific methylation. A) A simplified representation of the Methyl-Sensitive Restriction
Enzyme (MSRE) based Allele-Specific Methylation (ASM) assay. DNA is MSRE treated (left panels) and MSRE sites with methylated CpGs protected from
digestion (upper panels, Allele-A) while its homologous chromosomal region with unmethylated CpGs are not (lower panels, Allele-B). The DNA is
digested with StyI and NspI to form 200–1200 bp fragments, linkers ligated and DNA amplified to create amplicons that are hybridized to the array.
Only regions with protected MSRE sites (methylated CpG) are amplified and can hybridize to show signal on the array (final panel). B) Bioinformatic
detection of Allele-Specific Methylation (ASM) from Affymetrix SNP 6.0 arrays signals after MSRE digestion. In the scatter plot on the left, 4 different
expected states after MSRE digest at a heterozygous region are compared to the typical distribution of probe intensities observed within the HapMap
samples for the same MPR (here portrayed by light grey squares): biallelic methylation (dark grey circles), monoallelic A methylation (blue circles),
monoallelic B methylation (yellow circles) and finally biallelic lack of methylation (red circles). The primary calling method relies on feature extraction
by way of conversion of 2-dimensional A and B probe intensity data (scatter plot) from heterozygotes to log2(A/B) values and is compared against
the typical log2(A/B) distribution observed for this MPR within the HapMap samples (histogram, light grey). Simply put, MPRs diverging from this
distribution after MSRE treatment are called ASM. Using this method, biallelic unmethylated states have the potential to result in false positive ASM
calls as any log2(A/B) value would be based on background noise, so are filtered out by removing MPRS with low total intensities (highlighted here
with a red quarter-circle, for further information on how this filter was devised, see Figure S8).
doi:10.1371/journal.pone.0098464.g001
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PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e98464Figure 2. Types of allele-specific methylation candidates. Plots showing number of different categories of ASM candidates within the
microarray study sample population. Of the 242533 MPRs for which there were at least 6 heterozygotes within the population (left pie chart) we
detected some level of ASM in at least 116045 (left pie chart, green), of these we detected ASM in at least 6 samples in 12032 MPRs (left pie chart,
dark green). Of these 12032 ASM MPRs, we detected cis-regulated ASM in 9750 MPRs (right pie chart, solid blue or solid yellow), and random or
stochastic ASM in 2282 MPRs (right pie chart, mixed blue and yellow). Representation of patterns of allelic-choice in ASM within the microarray study
sample population. ASM allelic choice is shown at 28 ASM and 2 non-ASM MPRs for the 42 samples in our initial microarray sample population. Non-
heterozygous samples (white), samples with biallelic methylation (grey), and samples with ASM (blue and yellow) with methylation at either Allele-A
(yellow) or Allele-A (blue) are shown. MPRs are organized in columns to show those determined to have no ASM (first two columns), cis-regulated
ASM (both for Allele-A (3rd to 11th columns) and Allele-B (15th to final columns) or random ASM (12th to 14th columns).
doi:10.1371/journal.pone.0098464.g002
Table 1. Candidate cis-regulated ASM variants in phenotypically implicated SNPs.
cis-regulated ASM
mean number sd %
LD pruned SNPs 8147 323 100.0
Subset that is also: NHGRI GWAS SNP 90 4 1.1
Monocyte eQTL 1752 75 21.5
PBMC eQTL 906 34 11.1
Mean number of candidate cis-regulated ASM variants in ten random LD pruned (ld,0.3) sets of candidate cis-regulated ASM SNPs that are also in high LD (LD.0.8)
with a Genome Wide Association Study (GWAS) derived variant from the National Human Genome Research Institute (NHGRI) database or an eQTL in monocyteso r
peripheral blood monocytes (PBMCs), with accompanying standard deviations of the mean (sd).
doi:10.1371/journal.pone.0098464.t001
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evidence of ASM in our microarray data and acted as a negative
control.
Our results confirm both the presence of cis-regulated ASM at
the two positive control variants (rs943049 and rs9366927), and its
absence at the negative control variant (rs3738154), none of which
are associated with complex disease. More significantly, our results
show that three of the seven phenotypic associated variants
predicted to exhibit ASM (rs2762051, rs6569648, rs713875), also
show cis-regulated ASM in our bisulfite sequencing results, with at
least one MSRE associated CpG within each variant’s amplicon
having a Bonferroni adjusted p-value of less than 0.05, as
measured by a chi-square test of the association between the
allele and CpG’s cytosine methylation states (Table 2 and Table
S3). Similarly, one other phenotypic associated variant
(rs10491434) while not confirming cis-regulated ASM at an
MSRE associated CpG, did show cis-regulated ASM at a nearby
non-MSRE associated CpG. Notably, for all ASM associated
CpGs, the allele associated with methylation was consistent
between the microarray and sequencing analyses. Further analysis
of methylation patterns within individual samples confirms these
results, showing clear patterns of ASM with varying incidence
within the sample set (Figure 3, Figure S4, Figure 4, Figure S5 and
Figure S6).
Discussion
We present here an evaluation of genome-wide cis-regulated
ASM and it relation to expression and phenotypic variation. Our
initial screen identified candidate cis-regulated ASM variants that
are non-coding, functional eQTLS and/or are in high LD with
genetic variants associated with complex phenotypes. We extend-
ed this initial screen to confirm cis-regulated ASM at three of these
complex phenotype-associated variants in an independent popu-
lation. Our results suggest that cis-regulated ASM may provide a
mechanistic explanation for many of the non-coding genetic
changes observed in GWA studies.
In total, 254 unique variants from the NHGRI GWAS catalog
(Table S2) are in high LD with at least one candidate cis-regulated
ASM variant. Many DNA methylation marks show marked tissue
specificity and given recent results by Trynka et al. [4] suggesting
that the overlap of regulatory chromatin marks with phenotypi-
cally associated variation is cell type specific, further tissue specific
studies of ASM may reveal links to other variants within the
NGHRI GWAS catalog.
We completely validate three of the seven amplicons predicted
to exhibit cis-regulated ASM. Comparison of these confirmation
results with our intial microarray screen is complicated by the age
differences between our microarray population and our follow-up
population, with median ages of 83.5 and 24 years of age
respectively. Given the well-established relationship between
methylation variation and age [18–23], with even genetically
identical twins showing increased ‘‘epigenetic drift’’ over time
[21,24,25] a higher age range might be expected to be associated
with greater DNA methylation pattern variation [13]. However,
higher false positive rates within the initial screen cannot be ruled
out; broader interpretation of candidate ASM loci properties
should bear this caveat in mind.
Our microarray screen suggested that multiple eQTLs and
GWAS-derived variants show cis-regulated ASM and we confirm
three of these MSRE-related CpG methylation events in an
independent population. The three variants have been shown to
affect multiple phenotypes:
1) rs2762051 is a C/T variant located within the long non-
coding RNA DLEU1 and has been implicated in Celiac
disease [26].
2) rs713875 is a C/G variant located downstream of the
HORMAD2 and LIF genes that has been implicated in
multiple diseases, including Crohn’s disease [27], IgA
nephropathy [28] and early-onset inflammatory bowel disease
[29]. It is also an eQTL for MTMR3 [16] and a DNAse
sensitive quantitative trait loci for the chr22:28922487–
28922487 region [30].
3) rs6569648 is a C/T variant located within the second intron
of L3MBTL3 (Figure 4), for which it is also an eQTL [16];
this SNP is one of the hundreds associated with variation in
height.
A fourth variant, rs10491434 did not directly confirm our
MSRE-based microarray results but did show ASM at a nearby
(#bp) non-MSRE CpG. The rs10491434 SNP is a C/T variant
located within the 39UTR of the RefSeq IL7R gene (Figure 4), and
is in high LD with the rs3194051 variant implicated in ulcerative
colitis [31]. More recently, rs10491434 has been implicated in
AIDS progression [32]. Interestingly, this methylation phenotype
does not appear to originate from the rs10491434 variant. While
MSRE sites were screened for modifying SNPs, CpGs were not
and closer analysis of the affected CpG reveals the presence of a
variant, rs10491435, within the CpG site itself. This CpG
modifying variant is in perfect LD with rs10491434 and is likely
responsible for the observed cis-regulated ASM. This variant may
influence methylation at the nearby MSRE-CpG in the older
microarray population; its close proximity is well within the
previously ascribed limits to this local methylation influence [9].
Few studies have examined the association of allele-specific
methylation changes with phenotypic traits genome-wide. Allele-
specific methylation of MCHR1 is associated with BMI [33]. In
cancer progression, Kang et al. report an association of p14ARF
(CDKN2A) polymorphisms with the likelihood of methylation of
this gene within colorectal cancers [34], while Boumber et al.
report an indel polymorphism in the PDLIM4 that influences its
methylation in leukemia and colon cancer [35]. More recently,
case-control analyses by Liu et al [36] uncovered CpGs within the
MHC region which show an association between genotype, the
variance of methylation and risk for rheumatoid arthritis. Our
study has the advantages of the use of a genome-wide, unbiased
screen for allele-specific methylation through the use of a platform
specifically designed for differential allele detection. While the
results of Liu et al. show that assessment of the role of genetics and
methylation in disease progression can be approached by direct
study of affected individuals, untargeted studies of ASM such as we
present here can supplement these approaches to help identify
candidate loci for more intensive, targeted, studies. In that respect,
while our results suggest links between cis-regulated ASM at
rs10491434, rs2762051 and rs713875 and various autoimmune
related phenotypes, further targeted studies of individuals with the
relevant phenotypes are necessary to fully substantiate them.
Our choice of technology for the bisulfite confirmation assay
was strongly influenced by our desire to examine the association of
allele and methylation states without a priori knowledge of
genotype. As our microarray approach can only assay ASM in
heterozygotes, we did not want to exclude the possibility that we
would only observe cis-regulated ASM in the heterozygote state.
This required observation of the allele and CpG methylation states
on the same read; we chose 454 pyrosequencing as it produces
reads capable of spanning the distances between target CpGs and
variants. Unfortunately, we were unable to obtain quality results
Allele Specific Methylation at Disease Variants
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e98464Figure 3. Cis-regulated allele-specific methylation confirmation in an independent population. Heatmaps show percent methylation
status for a single CpG within the amplified regions of 3 different MPRs (rs10491434 (top row), rs6569648 (middle row) and rs943049 (bottom row))
for all samples (alternate allele homozygotes (1
st column), heterozygotes (2
nd column) and reference allele homozygotes. (3
rd column)); darker red
denotes higher methylation percentages within a sample at the CpG. The final column shows the –log10 p-values derived from chi-square tests for
association of methylation with one allele; darker blue results show greater evidence of cis-regulated ASM at the CpG in a particular sample. (CpGs
illustrated within this figure are marked with an asterisk in Figure 4).
doi:10.1371/journal.pone.0098464.g003
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insufficient reads mapping to these amplicons. This is likely at least
partially due to biased amplification during sequencing, but also to
non-optimal mapping due to extensive homopolymer-related gaps
in our reads, a known issue with the 454-pyrosequencing
technology (expected to be of even greater impact in the reduced
base space of bisulfite sequencing). Supporting this, initial attempts
to map these reads with the non-indel aware mapper Bowtie were
largely unsuccessful.
Our results have further implications for GWAS. We observe
incomplete penetrance of cis-regulated ASM in both our initial
screen and our bisulfite sequencing results, or put another way, a
lack of consistency in the occurrence of cis-regulated ASM within
a group heterozygous individuals [13]. This incomplete pene-
trance raises the possibility that genetic control of ASM may act as
a capricious mediator between a genetic variant and its associated
phenotypic outcome, introducing phenotypic variation to nomi-
nally identical genotypic backgrounds. This would be expected to
reduce the observed odds-ratios/effect-sizes of putative disease
causing variants in GWA studies. For instance, the rs713875
variant is only weakly associated with Crohn’s disease with an odds
ratio of ,1.08 [27]. It is possible that the local methylation state of
rs713875 may provide a more consistent predictor of disease. In
this respect, investigations integrating both genetic and of cis-
regulated ASM variation may help reveal variant in what has been
called ‘‘the grey zone’’ of GWA studies [37], comprised of sub-
significant GWAS signals that nonetheless play a role in disease.
Materials and Methods
These analyses were conducted under the auspices of protocols
approved by the institutional review board of Partners Healthcare
and Massachusetts Eye and Ear Infirmary. All participants signed
consent statements and research adhered to the tenets of the
Declaration of Helsinki
Microarray Study Population
The microarray study population for methylation analyses was
derived from the National Academy of Sciences-National
Research Council World War II Veteran Twin Registry [38].
Details of this study population have been previously described
[39]. DNA samples for methylation analyses were drawn from
whole blood samples from 42 total samples. Of these samples, 18
were singletons and 24 were drawn from 12 twin pairs. All samples
were genotyped once and all Affymetrix SNP 6.0 methylation
array based analyses run in duplicate.
Resequencing Study Population
Peripheral venous blood was obtained from healthy control
volunteers enrolled in The Brigham and Women’s Hospital
PhenoGenetic Project. The PhenoGenetic Project is a living tissue
bank that consists of healthy subjects who are re-contactable and
can therefore be recalled based on their genotype. 1,741 healthy
subjects .18 years old have been recruited from the general
population of Boston. They are free of chronic inflammatory,
infectious and metabolic diseases. Their median age is 24, and
62.7% of subjects are women.
For this study whole blood samples were derived from 86
phenotypically normal participants of European ancestry. Four of
these samples were subsequently discarded, two due to gender
mismatch and two due their status as EIGENSTRAT [40] outliers
for European ancestry.
Microarray Study Population Genotyping
Samples were genotyped on the Affymetrix SNP 6.0 (Santa
Clara, California) platform at the Broad Institute Center for
Genotyping and Analysis (Cambridge, MA). Each twin pair was
genotyped and analyzed with PLINK [41] to determine basic
quality assurance and quality control metrics.
Methyl-Sensitive Restriction Enzyme Digest
For the microarray study, 3 mg of genomic NA was digested at
37 degrees Celsius for 16 hrs with an in the methyl-sensitive
restriction enzyme (MSRE) cocktail including Aci I (60 units),
BsaH I (3.9 units), Hha I (7.5 units), Hpa II (7.5 units), and
HpyCH4 IV (30 units) (New England Biolabs), in a 200 ml reaction
volume with 1% BSA and 10% NEB buffer #4 (New England
Biolabs) and heat inactivated for 20 minutes at 60uC. Samples
Figure 4. Genomic context of cis-regulated allele-specific methylation events. Illustrations showing genomic context and individual CpG
methylation levels at three separate MPRs (rs10491434 (left), rs6569648 (middle) and rs943049 (right)). The chromosomal location of each amplicon is
demonstrated with an ideogram. and the RefSeq genes (orange) surrounding the amplicon (red line) shown below. A section (grey box) contracts to
the amplicon region itself to show the relative positions of the SNPs (black lines) and CpGs (blue lines) within the amplicons themselves (red bars);
methylation levels of the alternate (grey circles) and reference (yellow circles) alleles within samples heterozygous for the SNP are graphed below
each CpG. Asterixes (*) mark the CpGs illustrated within Figure 3.
doi:10.1371/journal.pone.0098464.g004
Allele Specific Methylation at Disease Variants
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e98464T
a
b
l
e
2
.
C
o
n
f
i
r
m
a
t
i
o
n
o
f
A
S
M
i
n
a
s
u
b
s
e
t
o
f
c
a
n
d
i
d
a
t
e
c
i
s
-
r
e
g
u
l
a
t
e
d
A
S
M
v
a
r
i
a
n
t
s
.
S
N
P
i
d
C
p
G
G
e
n
o
m
i
c
P
o
s
i
t
i
o
n
M
S
R
E
C
p
G
B
o
n
f
e
r
r
o
n
i
A
d
j
u
s
t
e
d
p
-
v
a
l
u
e
P
e
r
c
e
n
t
M
e
t
h
y
l
a
t
e
d
R
e
f
e
r
e
n
c
e
A
l
l
e
l
e
P
e
r
c
e
n
t
M
e
t
h
y
l
a
t
e
d
A
l
t
e
r
n
a
t
e
A
l
l
e
l
e
M
e
t
h
y
l
a
t
e
d
A
l
l
e
l
e
A
s
s
a
y
s
C
o
n
s
i
s
t
e
n
t
r
s
1
0
4
9
1
4
3
4
c
h
r
5
:
3
5
8
7
7
8
4
9
N
O
8
.
3
E
-
1
5
2
9
3
.
9
2
7
.
4
R
E
F
Y
E
S
c
h
r
5
:
3
5
8
7
7
8
4
9
Y
E
S
1
.
8
E
+
0
0
9
5
.
6
9
3
.
9
R
E
F
Y
E
S
r
s
2
0
2
1
7
1
6
c
h
r
6
:
9
0
9
4
0
9
7
6
N
O
2
.
1
E
-
0
2
8
9
.
9
8
7
.
5
R
E
F
N
O
c
h
r
6
:
9
0
9
4
1
0
9
0
Y
E
S
1
.
5
E
+
0
0
9
3
.
4
9
0
.
9
R
E
F
N
O
r
s
2
5
6
4
9
2
1
c
h
r
3
:
5
3
1
2
5
2
3
8
N
O
1
.
1
E
+
0
0
9
4
.
8
9
2
.
7
R
E
F
Y
E
S
c
h
r
3
:
5
3
1
2
5
2
5
6
N
O
4
.
8
E
-
0
1
9
5
.
4
9
2
.
9
R
E
F
Y
E
S
c
h
r
3
:
5
3
1
2
5
2
7
4
Y
E
S
1
.
0
E
+
0
1
8
7
.
5
8
7
.
5
A
L
T
N
O
c
h
r
3
:
5
3
1
2
5
2
7
1
Y
E
S
1
.
0
E
+
0
1
9
7
.
3
9
7
.
2
R
E
F
Y
E
S
c
h
r
3
:
5
3
1
2
5
1
6
4
Y
E
S
1
.
1
E
+
0
0
9
7
.
7
9
9
.
4
A
L
T
N
O
r
s
2
7
6
2
0
5
1
c
h
r
1
3
:
5
0
8
3
5
7
5
9
Y
E
S
3
.
4
E
-
3
6
7
1
.
5
3
9
.
1
R
E
F
Y
E
S
c
h
r
1
3
:
5
0
8
3
5
8
0
2
N
O
9
.
1
E
-
2
8
6
1
.
5
8
5
.
8
A
L
T
N
O
r
s
6
5
6
9
6
4
8
c
h
r
6
:
1
3
0
3
4
9
1
2
2
Y
E
S
1
.
8
E
-
1
9
4
4
.
0
2
0
.
9
R
E
F
Y
E
S
r
s
7
1
3
8
7
5
c
h
r
2
2
:
3
0
5
9
2
4
6
3
N
O
8
.
0
E
-
0
3
4
.
0
7
.
4
A
L
T
Y
E
S
c
h
r
2
2
:
3
0
5
9
2
4
7
5
N
O
5
.
9
E
-
0
3
1
.
8
4
.
4
A
L
T
Y
E
S
c
h
r
2
2
:
3
0
5
9
2
4
7
7
Y
E
S
2
.
9
E
-
0
2
2
.
4
4
.
7
A
L
T
Y
E
S
c
h
r
2
2
:
3
0
5
9
2
4
8
7
N
O
N
A
N
A
N
A
A
L
T
Y
E
S
c
h
r
2
2
:
3
0
5
9
2
4
9
3
N
O
2
.
0
E
-
0
3
2
.
0
4
.
9
A
L
T
Y
E
S
c
h
r
2
2
:
3
0
5
9
2
8
7
1
Y
E
S
2
.
8
E
+
0
0
1
3
.
6
5
.
4
R
E
F
N
O
c
h
r
2
2
:
3
0
5
9
2
9
4
6
Y
E
S
1
.
0
E
+
0
1
1
1
.
1
1
1
.
1
A
L
T
Y
E
S
r
s
8
8
4
4
8
8
c
h
r
8
:
1
0
1
8
9
8
3
6
9
Y
E
S
1
.
0
E
+
0
1
8
6
.
6
8
6
.
6
A
L
T
N
O
c
h
r
8
:
1
0
1
8
9
8
5
3
3
Y
E
S
1
.
0
E
+
0
1
4
2
.
0
4
1
.
9
R
E
F
Y
E
S
c
h
r
8
:
1
0
1
8
9
8
6
7
3
Y
E
S
1
.
0
E
+
0
1
9
3
.
3
9
3
.
3
A
L
T
N
O
r
s
9
3
6
6
9
2
7
c
h
r
6
:
3
7
0
2
7
3
9
1
Y
E
S
1
.
4
E
-
1
9
6
7
.
8
8
6
.
9
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
4
0
3
N
O
1
.
2
E
-
3
0
7
7
.
4
9
5
.
7
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
4
1
5
N
O
9
.
4
E
-
7
6
5
4
.
3
9
1
.
9
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
4
2
4
N
O
2
.
6
E
-
9
1
5
4
.
7
9
4
.
6
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
4
2
6
N
O
9
.
5
E
-
1
0
5
4
2
.
0
8
9
.
6
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
3
1
5
Y
E
S
2
.
3
E
-
8
9
7
.
3
4
9
.
8
A
L
T
Y
E
S
c
h
r
6
:
3
7
0
2
7
1
7
8
Y
E
S
4
.
8
E
-
7
9
1
5
.
8
6
7
.
9
A
L
T
Y
E
S
r
s
9
4
3
0
4
9
c
h
r
1
3
:
2
5
1
8
0
3
4
6
Y
E
S
2
.
3
E
-
0
2
9
6
.
6
9
4
.
2
R
E
F
Y
E
S
c
h
r
1
3
:
2
5
1
8
0
2
7
9
Y
E
S
9
.
5
E
-
2
8
8
9
0
.
6
2
9
.
5
R
E
F
Y
E
S
c
h
r
1
3
:
2
5
1
8
0
4
2
2
N
O
0
.
0
E
+
0
0
8
9
.
4
1
6
.
3
R
E
F
Y
E
S
c
h
r
1
3
:
2
5
1
8
0
2
2
8
Y
E
S
0
.
0
E
+
0
0
9
0
.
1
1
2
.
2
R
E
F
Y
E
S
c
h
r
1
3
:
2
5
1
8
0
6
2
4
N
O
6
.
7
E
-
1
4
9
5
.
7
7
4
.
2
R
E
F
Y
E
S
r
s
3
7
3
8
1
5
4
c
h
r
1
:
2
0
5
0
6
4
1
3
3
Y
E
S
1
.
0
E
+
0
1
9
8
.
2
9
8
.
2
A
L
T
N
A
Allele Specific Methylation at Disease Variants
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e98464were ethanol precipitated, washed in 70% ethanol and resus-
pended in reduced EDTA TE (5 mM Tris, 0.1 mM EDTA) at
50 ng/ml. All samples underwent the regular Affymetrix SNP 6.0
hybridization procedure in duplicate; samples were digested with
the Nsp I and StyI restriction enzymes, fragments of 100–1200 bp
(containing the polymorphic sites to be assessed) PCR amplified,
and the resulting amplicons labeled and hybridized to the array.
Methyl-Sensitive Restriction Enzyme Digest Validation
Efficacy of the independent methylation sensitive restriction
enzymes was determined by examining MSRE action on
amplicons with solitary cut sites for a component MSRE in a
control mix run alongside the study samples. Our results showed
amplicons with single MSRE cut sites, with the exception of HhaI,
exhibited greatly reduced combined probe intensities as compared
to amplicons with no MSRE sites (or MSRE Negative Regions
(MNRs)) (Figure S7). Amplicons with only HhaI sites (6132 in
total) were removed from further analyses.
Methylation Array Quality Control
To eliminate replicates with poor hybridizations, the un-
normalized probe intensities of the replicates of MSRE digested
samples were compared by linear regression. All replicate
coefficients of determination were within 2.5 standard deviations
of the mean of the entire sample set (mean=0.919, standard
deviation=0.125). After normalization, the mean coefficient of
determination was 0.94 with a standard deviation of 0.028.
Methylation Array Normalization and ASM Detection
For further details on methods development, see Supporting
Information (Information S1, Figure S8, Figure S9, Figure S10,
Figure S11, Figure S12, Figure S13 and Table S4). Briefly,
invariant probesets were quantile normalized between arrays and
normalized values for variant probesets interpolated from the
normalized invariant probesets derived from their respective
arrays. After various levels of technical filtering by multiple
criteria (Figure S1) allele-specific methylation at heterozygous
SNPs was detected as a sample and SNP-specific normalized
deviation from the HapMap derived heterozygote relative probe
intensity. To account for inter-probeset variation we standard
normalized all post-MSRE treatment MPR log2(A/B) values
against the HapMap distribution for that MPR to derive a
Standard Score; MPRs with different HapMap log2(A/B)
distributions then had comparable Standard Score distributions.
To account for inter-sample technical variability within this
standard score we used the samples’ MNR Standard Score
distributions (which are not expected to vary between samples) to
determine the final ASM calls; MPRs with values lower than the
2.5 and 97.5 percentiles of the MNR distribution for a sample
were called ASM (Figure 1). All microarray data are available
upon request from Dr. Seddon.
GWAS and EQTL Enrichment Analyses
Independent GWAS variants from the NHGRI GWAS Catalog
[17] were restricted to annotated results with annotated p-values of
less than 1610
27 and at least 500 individuals in the ‘‘Total Initial
Sample Size’’. All sets of SNPs were pruned to produce subsets
with pair wise linkage-disequilibrium (LD) values of no more than
0.3. Minor allele frequencies (MAFs) for MAF matching between
sets of SNPs were calculated from the 1000 genomes project.
For eQTL derivation, associations between SNP genotypes and
adjusted expression values were conducted using Spearman Rank
Correlation (SRC). For the cis-eQTL analysis, we considered only
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genes. Significance of the nominal p-values was determined by
comparing the distribution of the most significant p-values
generated by permuting expression phenotypes 10,000 times
independently for each gene. Significant cis-eQTLs were those
with a nominal association P-value greater than the 0.05 tail of the
minimal P-value distribution resulting from the SNP’s associations
with 10,000 permuted sets of expression values or each gene.
Enrichment of cis-regulated ASM in eQTLs was calculated by
chi-squared test. Random LD pruned SNPs from sets of both non-
ASM SNPs and cis-regulated ASM SNPs (10 sets each) were
examined to determine the proportion that were also found within
sets of eQTL SNPs derived from either monocytes or peripheral
blood mononuclear cells (PBMCs).
Resequencing Primer Design
As most of the candidate target amplicons were larger than the
maximum read length (minimum length of 221 bp and a median
length of 362.5 bp) typically obtained with Illumina technologies,
we employed 454 large-scale parallel pyrosequencing in order to
examine SNP and CpG site methylation status on the same read.
Primers for bisulfite PCR (BSP) amplification were designed with
Methprimer [42] and BiSearch [43] to uniquely amplify fragments
of less than 500 bp encompassing the MSRE sites and target SNP,
when possible. For some variants, two amplicons were necessary to
cover all predicted MSRE sites and the target SNP, for others, it
was necessary to use proxy SNPs to report the status of target
SNPs too far away from MSRE sites assayed by the microarray
assay. All amplifications were strand specific and were designed to
allow observation of the SNP status after bisulfite conversion and
amplification; for C/T SNPs, the guanine strand was amplified.
Primer sequences (against bisulfite converted DNA) and amplicon
genomic locations for all amplicons can be found in Table S5.
Resequencing Bisulfite PCRs
The set of DNA samples from 82 phenotypically normal
individuals were bisulfite converted, and the initial set of the 32
target regions amplified. DNA was bisulfite converted with the
Qiagen EpiTect 96 Bisulfite Kit according to the standard
protocol in the manufacturer’s instructions by centrifugation
without carrier tRNA. Converted DNA was quantitated by
Nanodrop and separate aliquots amplified in 96 well plates for
each amplicon (Figure S14). Each 20 ul PCR reaction comprised
10 ng of converted DNA, 1 unit of Qiagen HotStarTaq Plus, 50
picomoles of each primer (2.5 mM final concentration), 16 PCR
buffer, and 200 nanomoles of dNTPs (10 mM final concentration)
and was run for 35 cycles. Melting temperatures and extension
times were empirically tested for each primer set to a) optimize
product yield while b) reducing amplification of unconverted DNA
and off-target products. Final individual amplification conditions
can be found in the Supplementary Information (Table S5). A
random subset of amplification products from each plate was
visually confirmed by agarose gel electrophoresis and all ampli-
fication products quantitated by Picogreen. Equimolar amounts
from each target’s amplification products were mixed for each
individual and prepared for bar-coded 454 Pyrosequencing.
Resequencing Read Alignment
Pooled reads were separated by individual according to bar-
coded index. Sff formatted reads were converted to fastq format
with sff_extract version 0.2.13 and adapter and low quality
sequences clipped; reads shorter than 100 were removed using
fastx_clipper. Reads were non-directionally aligned to unconvert-
ed amplicon sequences with Bismark [44]. To adjust for small
insertions/deletions which result from 454 sequencing’s known
homopolymer issues [45], we ran Bismark with the Bowtie 2
gapped aligner with a multi-seed length of fifteen with one
mismatch. Up to 20 consecutive seed extension attempts were
attempted before accepting a read alignment. After barcode
filtering, reads mapped to the amplicon reference sequence by
Bismark with Bowtie 2 aligner at a mean of 49.6%.
Bisulfite conversion rates on all reads were calculated with the
Bismark methylation_extractor script (Figure S15). Individual
reads were not filtered by conversion rate to avoid biases against
CpG methylated reads which might result from removal of reads
containing correlated methylated non-CpGs (i.e. CHG and
CHH). Instead we looked for samples with failed bisulfite
conversions, i.e. samples with a mean conversion rate lower than
95%. Examination of bisulfite conversion at non-CpG cytosines
showed successful conversion in all samples, with an average
conversion rate of 98.7%. In order to obtain reads with
information for both the SNP and MSRE site status, reads which
did extend over both the amplicon’s target SNP and MSRE sites
were then discarded.
SNP Genotyping and Quality Control
Genotypes at target SNPs were called in VCF format with
samtools mpileup [46] with extended BAQ, and a BAQ cutoff of
10; indels were not called. To ensure quality analyses, we filtered
our samples and amplicons based on coverage depth, genotype
quality, Hardy-Weinberg equilibrium with the sample population,
and agreement expected minor allele frequency. Samples or
amplicons with consistently low confidence genotypes (depth of
coverage less than 20, genotype quality less than 20) at the target
SNP in a majority (.50%) of samples or amplicons were discarded
(Figure S16). Hardy-Weinberg and minor allele frequencies for all
amplicon target SNPs were calculated for the population with
VCFtools [47]. Amplicons with SNPs deviating from the expected
Hardy-Weinberg equilibrium (p,0.01) and any amplicons whose
minor allele frequency showed a relative mean difference of more
than 0.25 from the expected CEU minor allele frequency
(HapMap release 27) were discarded. Filtering amplicons or
samples with low read coverage or called genotype quality in a
majority of our set of samples or amplicons respectively removed
21 of the 32 amplicons and 12 of the 82 samples leaving 11
amplicons and 70 samples. Further filtering based on deviation
from the expected Hardy-Weinberg equilibrium (p,0.01), re-
moved 1 amplicon. All remaining amplicons also had minor allele
frequencies with relative mean differences of less than 0.2 from the
expected CEU minor allele frequency (HapMap release 27)
(Figure S17).
Supporting Information
Figure S1 Technical filtering. MPRs were filtered for quality
and potential technical artifacts by multiple criteria. Of the
,910,000 amplicons on the Affymetrix SNP6.0 array,
,,150,000 had no predicted MSRE sites, and were used to
normalize between arrays but discarded from downstream
analyses. We also removed amplicons with MSRE sites that did
not perform well on our HapMap reference set; ,70,000
amplicons had no calls across the entire HapMap samples, and
,180,000 had poor separation (or low ‘‘discrimination’’) between
the 3 log2 (A/B) distributions for the 3 genotype classes (AA, AB
and BB). The potential for artifacts arising from polymorphisms in
MSRE sites was eliminated in a similar manner to that previously
described [9]. Briefly, we excluded all SNPs on the Affymetrix
array residing on amplicons containing any polymorphism in an
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individuals of European descent from the 1000 Genomes Project
data [48]. Although this filter may discard SNPs that do not reside
on amplicons with MSRE site polymorphisms in the individuals
examined here, we conservatively chose to ensure robust analyses
by eliminating any SNP expected to appear at least once in the
microarray study population.
(PDF)
Figure S2 Detection of previously identified allele-
specific methylation events. Shown are the standard scores
(or Standard Scores) of heterozygote samples after probeset
normalization against the log2 (A/B) distribution of heterozygote
undigested HapMap samples for four MPRs found in genomic
regions known to be associated with allele-specific methylation;
rs220030 is a SNP within the imprinted SNRPN locus (A);
rs2107425 is a SNP located ,2 kb upstream of the imprinted H19
locus (B); rs6494120 is an intergenic SNP located ,11 kb
upstream of GCNT3 (C) and rs943049 is an intergenic SNP
located ,75 kb upstream of ATP12A (D). Red and blue circles
denote MSRE treated and untreated samples respectively. Open
and closed circles denote samples for which an allele-specific
methylation event was and was not observed, respectively.
Standard scores with a negative value denote allele-specific
methylation of the B allele (i.e. log2 (A/B),0) and those with a
positive value denote allele-specific methylation of the A allele (i.e.
log2 (A/B).0) (base identities of the A and B alleles are indicated
for each variant). For MPRs within known imprinted regions
(panels A and B), an approximately equal number of allele-specific
methylation events at the A and B alleles is observed, consistent
with a pattern of allele-specific methylation based on allelic parent-
of-origin within our sample population. The differential methyl-
ation patterns of MPRs found in genomic regions previously
associated with cis-regulated allele-specific methylation (panels C
and D) are consistent with previous results, i.e. only one allele is
associated with methylation.
(PDF)
Figure S3 Genomic properties of cis-regulated allele-
specific methylation candidates. Non-genic localization
(upstream or downstream of annotated gene, blue) versus genic
localization (59UTR, 39UTR, exons or introns of an annotated
gene, red) of candidate cis-regulated ASM regions (A). Non-genic
(upstream or downstream of annotated gene) candidate cis-
regulated ASM regions are located a median distance of 129 kb
from the closest gene (B).
(PDF)
Figure S4 Assessing allele-specific methylation in an
independent population. Results for all individual CpGs of the
ten amplicons (A - rs10491434_BSP; B - rs2021716_BSP; C -
rs2564921_BSP; D - rs2762051_BSP; E - rs3738154_BSP; F -
rs6569648_BSP; G - rs713875_BSP; H - rs884488_BSP; I -
rs943049A_BSP; J - rs9366927_BSP) are shown. Heatmaps show
percent methylation status for single CpGs within the amplified
regions of MPRs for all samples (alternate allele homozygotes (1
st
column), heterozygotes (2
nd column) and reference allele homo-
zygotes. (3
rd column)); darker red denotes higher methylation
percentages within a sample at the CpG. The final column shows
the –log10 p-values derived from chi-square tests for association of
methylation with one allele; darker blue results show greater
evidence of cis-regulated ASM at the CpG in a particular sample.
(PDF)
Figure S5 Genomic context of amplicons and methyla-
tion events. Illustrations showing genomic context and individ-
ual CpG methylation levels for ten amplicons (A -
rs10491434_BSP; B - rs2021716_BSP; C - rs2564921_BSP; D -
rs2762051_BSP; E - rs3738154_BSP; F - rs6569648_BSP; G -
rs713875_BSP; H - rs884488_BSP; I - rs943049A_BSP; J -
rs9366927_BSP) are shown. The chromosomal location of each
amplicon is demonstrated with an ideogram and the RefSeq genes
(orange) surrounding the amplicon (red line) are shown below. A
section (grey box) contracts to the amplicon region itself to show
the relative positions of the SNPs (black lines) and CpGs (blue
lines) within the amplicons themselves (red bars); methylation
levels of the alternate (grey circles) and reference (yellow circles)
alleles within samples heterozygous for the SNP are graphed below
each. The final bottom plot shows, for individual heterozygote
samples, the results of chi-square tests of the association between
allele state and individual CpG’s cytosine methylation states,
reported as–log10 transformed p-values.
(PDF)
Figure S6 Methylation patterns of amplicons. Illustrations
showing methylation patterns for ten amplicons at both a
population level and within a representative individual. ‘‘Lollipop’’
plots show both methylation calls for 30 randomly drawn reads
from each allele from the entire population (left plot) and for a
representative heterozygous individual for that amplicon (right
plot). Representative individuals were selected by finding the
individual closest to the median chi-square based p-value for the
CpG with the highest likelihood of ASM based on lowest mean
chi-square based p-value. CpG methylation status is shown in
black (methylated) and white (unmethylated) while SNP status is
shown in blue (reference allele) and orange (alternate allele). CpGs
or SNPs on a read without information (typically due to gaps in the
read) are displayed in grey.
(PDF)
Figure S7 Individual assessment of methylation-sensi-
tive restriction enzyme digest efficacy. Density plots are
shown for assayed probe intensities for amplicons with single
MSRE sites for each of the five MSRE enzymes used as well as for
MNRs (UNCUT). Intensities are expressed as the assayed total
intensities for these amplicons normalized against the total
intensities for these amplicons in the HapMap samples. All
MSREs with the exception of HhaI exhibited reduced overall
intensities as compared to amplicons without MSRE sites (MNRs/
UNCUT).
(PDF)
Figure S8 Derivation of intensity ratio cutoff. To filter out
potential false positives derived from biallelic unmethylated MPRs
a filter based on the intensity ratio of the MSRE treated MPRs as
compared to that of the HapMap reference samples. The
threshold was chosen to screen out biallelic unmethylated MPRS
while still passing any ASM MPRs (which would be expected to
show reduced overall intensities as compared to biallelic
methylated MPRs). The final value of this filter was based on
observation of this intensity ratio in 1:1 unmethylated control
mixes, which are expected to model the properties of monoallelic
methylated MPRs at all assayed amplicons. At an intensity ratio
value of 0.2, only 0.2% of these mock ASM MPRs were filtered
out.
(PDF)
Figure S9 Assessment of traditional Affymetrix SNP6.0
array normalization methods. Scatter plots (left panels) and
histograms (right panels) of un-normalized (top panels), median
normalized (middle panels) and quantile normalized (bottom
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digested samples of an unmethylated control are shown.
(PDF)
Figure S10 Method of MNR selection. Amplicons were
chosen as MNRs based on two criteria: 1) assay based size
selection of amplicons results in a final amplicon size range of 200–
1200 bp and 2) bioinformatic prediction of MSRE site locations.
These criteria allow selection of 3 classes of MNR amplicons
expected to show no effect of MSRE digestion: a) those with both
NspI and StyI amplicons of 200–1200bp with no MSRE sites (1st
alternative) and those with either b) NspI amplicons of 200–
1200 bp with no MSRE sites and StyI amplicons outside this size
range (2nd alternative, top) or c) StyI amplicons of 200–1200 bp
with no MSRE sites and NspI amplicons outside this size range
(2nd alternative, bottom).
(PDF)
Figure S11 MPRs show lower combined probe intensi-
ties relative to MNRs after MSRE digest. Scatter plot (top
panel) and density plots (bottom panels) of total probe intensities
before (top panel and bottom left panel) and after MSRE digestion
(top panel and bottom right panel) for amplicons with (MPRs - in
red) and without (MNRs - in blue) MSRE sites in an unmethylated
control sample. MPRs show a pronounced shift to lower intensities
after MSRE digestion.
(PDF)
Figure S12 Allele frequencies vary with MSRE digest for
MPRs but not MNRs in control methylation mixes.
Scatter plots of A allele frequencies (probe A intensity/(probe A
intensity + probe B intensity) for amplicons with (MPRs - in red)
and without (MNRs - in blue) MSRE sites from two 50:50 E44-
H16 control mix samples, one where one sample has H16
methylated and E44 unmethylated (y-axis) and the other H16
unmethylated and E44 methylated (x-axis). In the top panel,
MPRs where E44 contributes the A allele are shown and in the
bottom panel, E44 contributes the B allele. MSRE digest does not
change the distribution for MNRs but shifts those of MPRs
towards the axis of the mix with the methylated A allele.
(PDF)
Figure S13 Assessment of MNRs based quantile inter-
polation normalization method in control methylation
mixes. Scatterplots are shown of the probe A intensity values of
un-normalized (left panels) and normalized (right panels) of two
replicates from two separate reciprocal 50:50 E44:H16 control
mixes. In these 50:50 mixes, only one of the samples is methylated;
in the top panels, the E44 sample is methylated and the H16
unmethylated, in the bottom panels the H16 sample is methylated
and the E44 sample unmethylated. The MNR quantile interpo-
lated normalization based method used greatly reduced variation
between replicates.
(PDF)
Figure S14 Bisulfite PCR methods. A simplified represen-
tation of the bisulfite PCR sequencing assays. Sample DNA was
plated in 96 well plates, bisulfite converted and aliquoted into
separate 96 well plates for each amplification target (left panel).
Each 96 well plate was subjected to bisulfite-specific PCR (BSP),
amplifications were combined in equimolar amounts by individual
into a single 96 well and bar-coded before sequencing. Primers
were designed to flank both the target SNP (here a G/A SNP on
the top strand, middle and right panels) and CpG, amplify only
bisulfite converted DNA and be strand specific in a manner that
allowed allele identification after bisulfite conversion. Example
amplifications for a scenario where the G-allele is not associated
with CpG methylation (middle panel) and the A allele is associated
with a methylated CpG (right panel) are shown. Note that strand
specific amplification of the C/T SNP on the bottom strand would
not allow allele identification after bisulfite conversion.
(PDF)
Figure S15 Bisulfite conversion rates. Distributions of
median bisulfite conversion rates for all non-CpG cytosines in
each amplicon are shown for each sample. Both histograms (grey)
and density plots (orange) are shown.
(PDF)
Figure S16 Amplicon and sample genotype coverage
and qualities. Target SNP read coverage (A and C) and
genotype quality (B and D) distributions across all samples for each
amplicon (A and B) or across all amplicons for each sample (C and
D) are shown. Amplicons failed this test (orange filled distributions)
if the majority of samples had either less than 20-fold coverage or
genotype qualities below 20. Amplicons that passed these quality
filters (grey filled distributions in both panels A and B) were carried
forward. Similarly, samples failed these tests if the majority of
amplicons had either less than 20-fold coverage or genotype
qualities below 20.
(PDF)
Figure S17 Hardy Weinberg Equilibrium and allele
frequency based amplicon filtering. Reference allele
frequencies and heterozygote frequencies for assayed variants. A)
Observed versus expected (HapMap) reference allele frequencies
are shown. Colors of plotted data reflect the relative mean
difference of the observed minor allele frequency from the
expected CEU minor allele frequency (HapMap release 27). B)
Observed versus expected heterozygote frequencies as based on
observed allele frequencies. Colors of plotted data reflect the p-
values from of an exact test as defined by [49].
(PDF)
Table S1 MPR ASM levels are significantly higher than
expected from MNR allele-specific methylation levels.
Shown are numbers of heterozygous MPRs assessed for ASM
within each sample, the expected number of ASM MPRs based on
the MNR Standard Score distribution (i.e. 95% non-ASM, or 5%
ASM), the actual observed number, fold increase over expected
and the associated chi-square based p-value.
(XLS)
Table S2 NHRI GWAS SNPs in high LD with candidate
cis-regulated ASM SNPs. Details are shown for both NHGRI
variants in high linkage disequilibrium with cis-regulated ASM
variants and for genes regulated by eQTLs that are also cis-
regulated ASM variants. Study details for the NHGRI variants
and the allelic association counts observed in the microarray assay
are also shown.
(XLS)
Table S3 Detailed confirmation of ASM by sequencing
in a subset of candidate cis-regulated ASM variants.
Results from microarray and next-generation bisulfite sequencing
ASM assays of ten variant-containing regions. For each amplicon
region the table shows the variant and its categorization.
Autoimmune variants that exhibited ASM in the microarray
study are labeled ‘‘AI ASM’’, similar non-autoimmune NHGRI
variants are labeled ‘‘NHGRI ASM’’. ‘‘Known ASM’’ variants
have been previously shown to exhibit ASM. ‘‘Non ASM’’ variants
did not exhibit ASM in the microarray study. For the bisulfite next
generation sequencing analyses, the table shows the CpG position
within the amplicon and whether it is found within an MSRE site;
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conversion; the number of methylated and unmethylated CpGs
associated with the reference and alternate alleles and the
unadjusted and Bonferroni adjusted Chi-square p-values of those
associations. The allele with the highest number percentage of
methylated reads was designated the most frequently methylated
allele (REF=reference, ALT=alternate). For the microarray
data, the number of heterozygotes that were observed with ASM
associated with either the ‘‘A’’ or ‘‘B’’ alleles were used to
determine the identity of the most frequently methylated allele
which was matched against the most frequently methylated allele
in the sequencing data. within the microarray and next-generation
studies. For all CpGs that were within MSRE sites and showed
significant association of methylation with an allele in the
sequencing assay, the methylated allele matched that of the
microarray assay.
(XLSX)
Table S4 MNR properties. Details about the genomic
location and MSRE sites present on MNR NspI and StyI based
amplicons are shown. For each of the NspI and StyI amplicons,
the genomic location and amplicon size are presented. The
number of each of the 5 potential MSRE types (AciI, BsaHI,
HhaI, HpaII and HpyCH4IV) within the amplicon are shown
before the bracket. Within the bracket, the first number denotes
the number of dbSNP-derived variants that could add an MSRE
site while the second number denotes the number, which could
remove an MSRE site.
(XLSX)
Table S5 PCR properties. Properties of regions assayed by
bisulfite next-generation sequencing. For each amplicon, this table
reports its intended purpose of the amplicon, whether it be as
controls like CpG islands and X-chromosomal, imprinted and
known ASM regions, or as confirmation of the microarray results,
like regions without ASM (Non ASM), regions with random ASM
or regions with linked variants associated with either NGHRI or
autoimmune phenotypes. The table also reports the identity of the
variant within the amplicon (‘‘reporting variant’’), the linked
NHGRI/autoimmune variant, the sequences of the bisulfite PCR
primers, the melting temperature used for the bisulfite PCR, the
predicted product length and the genomic region amplified by the
bisulfite PCR.
(XLSX)
Information S1 Supplementary methods and referenc-
es.
(DOC)
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